The inhibitory effect of rBCG on EB virus-positive tumours using an EB virus fusion gene.
Appl Microbiol Biotechnol
; 106(1): 185-195, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-34854938
ABSTRACT
At present, studies have found that latent Epstein-Barr virus (EBV) infection is associated with a variety of human tumours, and a vaccine is not available in this field. In this research, RT-PCR was used to obtain BZLF1 (immediately expressed early antigen Z) and LMP2 (latent membrane protein 2) cDNA from EBV. A ZLP2 fusion gene containing a linker sequence that encoded the polypeptide (Gly4Ser)3 was obtained using the sequence splicing overlap extension method. Then, ZLP2 was inserted into pMV261 cells, and the recombinant plasmid pMV-ZLP2 was transformed into BCG competent cells. After EB virus-positive tumour cell (NPRC18) cancer models were established with C57BL/6 J mice, tumour weight, tumour formation time and mouse survival conditions were analyzed, and flow cytometry was used to analyze the quantities of CD8 + and CD4 + T cells. HE staining was used to detect and analyze lymphocyte infiltration, and statistical analysis was used to analyze the immunological effect of recombinant BCG (rBCG). Compared with the control group, rBCG could significantly prolong the survival time of mice, slow tumour growth and delay tumour formation time. Recombinant BCG exhibits an obvious immune effect in mice and an inhibitory effect on EBV-positive cancer.Key points⢠AZLP2 fusion gene with BZLF1 and LMP2 of EB virus was constructed.⢠ZLP2 fusion gene was expressed with rBCG.⢠rBCG with ZLP2 has an obvious effect on EBV-positive cancer.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Epstein-Barr Virus Infections
/
Neoplasms
Limits:
Animals
Language:
En
Journal:
Appl Microbiol Biotechnol
Year:
2022
Document type:
Article
Affiliation country: